Provided by Tiger Trade Technology Pte. Ltd.

NovaBay Pharmaceuticals

0.7601
+0.00831.10%
Post-market: 0.80560.0455+5.99%19:59 EST
Volume:1.77M
Turnover:1.46M
Market Cap:95.78M
PE:1.63
High:0.9400
Open:0.7893
Low:0.7600
Close:0.7518
52wk High:19.95
52wk Low:0.4600
Shares:126.01M
Float Shares:4.98M
Volume Ratio:1.11
T/O Rate:35.55%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.4666
EPS(LYR):-2.5347
ROE:-516.26%
ROA:-86.98%
PB:-35.70
PE(LYR):-0.30

Loading ...

NovaBay Pharmaceuticals Inc. Announces Date for Upcoming Special Meeting of Stockholders

Reuters
·
Jan 31

Amex Halt Add Info Lst 2.110000

THOMSON REUTERS
·
Jan 28

Small U.S. Stocks Decrease; NovaBay Pharmaceuticals Posts Biggest Loss

Dow Jones
·
Jan 21

Top Midday Decliners

MT Newswires Live
·
Jan 21

NovaBay Pharmaceuticals Reports At-The-Market Equity Program

MT Newswires Live
·
Jan 21

NovaBay trading halted, volatility trading pause

TIPRANKS
·
Jan 20

Amex Halt Add Info Lst 9.690000

THOMSON REUTERS
·
Jan 20

NovaBay Pharmaceuticals Inc - Files for Offering of up to $100 Mln Common Stock - SEC Filing

THOMSON REUTERS
·
Jan 20

Assessing NovaBay Pharmaceuticals (NBY) Valuation After Digital Asset Financing And SKY Token Treasury Shift

Simply Wall St.
·
Jan 19

NovaBay falls -17.1%

TIPRANKS
·
Jan 13

Amex Halt Add Info Lst 10.690000

THOMSON REUTERS
·
Jan 13

Small U.S. Stocks Move Upward; NovaBay Pharmaceuticals Climbs Highest

Dow Jones
·
Jan 10

NovaBay Pharmaceuticals Reports Turnaround in Earnings

TIPRANKS
·
Nov 14, 2025

NovaBay Pharmaceuticals Inc. Files Initial Beneficial Ownership Statement for CEO and Director Michael Kazley

Reuters
·
Oct 21, 2025

NovaBay Pharmaceuticals, Inc. Regains Compliance With Nyse American Continued Listing Standards

THOMSON REUTERS
·
Oct 21, 2025

NovaBay Pharmaceuticals, Inc. Regains Compliance with NYSE American Continued Listing Standards

GlobeNewswire
·
Oct 21, 2025

NovaBay Pharmaceuticals - on Oct 16, Michael Kazley Appointed as CEO and Chairman - SEC Filing

THOMSON REUTERS
·
Oct 20, 2025

NovaBay Pharmaceuticals Sells Preferred Shares and Pre-Funded Warrants Totaling $18 Million

Reuters
·
Oct 20, 2025

NovaBay Pharmaceuticals Inc - David Lazar Resigns as CEO - SEC Filing

THOMSON REUTERS
·
Oct 10, 2025

NovaBay Pharmaceuticals announces resignation of CEO David Lazar and transfer of preferred stock to new investors

Reuters
·
Oct 10, 2025